

FACSIMILE TRANSMISSION

Transmission problems: Sharon Parulan

Brobeck

ATTORNEYS AT LAW

November 19, 2001Brobeck, Phleger & Harrison LLP
1333 H Street N.W.
Suite 800
Washington, D.C. 20005
PHONE 202.220.6000
FAX 202.220.5200
www.brobeck.com

PAGES TO FOLLOW COVER	12	USER ID	100612	CMID NUMBER	031853.0003
-----------------------	----	---------	--------	-------------	-------------

TO

RECIPIENT	COMPANY	TELEPHONE	FAX
Examiner C. Evans	PTO		703-746-5035

FROM

SENDER	EMAIL	TELEPHONE	FAX
Rodger Tate	RTate@brobeck.com	202-220-5225	(202) 220-5200

MESSAGE

Per our telephone conference

P R I V I L E G E D A N D C O N F I D E N T I A L

All information transmitted hereby is intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and mail the original message to us at the above address.

B

November 19, 2001

BROBECK, PHLEGER & HARRISON LLP
1333 H STREET N.W.
SUITE 800
WASHINGTON, D.C. 20005
TELEPHONE 202.220.6000
FACSIMILE 202.220.5200

In re Patent Application of:

Ralph W. BLUME et al.

Application No.: 09/559,542

Filed: April 28, 2000

Title: GUAIFENESIN SUSTAINED RELEASE FORMULATION AND TABLETS

Attorney Docket No.: 031853.0003

Group Art Unit: 1615

Examiner: C. Evans

BOX AF

Commissioner for Patents

Washington, D.C. 20231

Transmitted herewith is an amendment in the above-identified application. Fees have been calculated as shown below:

CLAIMS AS AMENDED						
	Claims Remaining After Amendment	Highest Number Previously Paid For	Extra	Rate		Amount
				Large Entity	Small Entity	
Number of Claims in Excess of 20	59	32	27	\$ 18.00	\$ 9.00	\$ 243.00
Independent Claims in Excess of 3	3	3	0	\$ 80.00	\$ 40.00	\$ 0.00
First Presentation of Multiple Dependent Claims				\$ 270.00	\$ 135.00	\$ 0.00
Extension Fee:	a) One Month			\$ 110.00	\$ 55.00	
	b) Two Months			\$ 390.00	\$ 195.00	
	c) Three Months			\$ 890.00	\$ 445.00	
	d) Four Months			\$ 1390.00	\$ 695.00	
	e) Five Months			\$ 1890.00	\$ 945.00	
Other:						\$ 0.00
TOTAL FEE DUE						\$243.00



No additional fee is required.



A check in the amount of \$ _____ is attached.

Charge \$ 243.00 to Deposit Account No. 50-1640.

Charge any additional fees or credit any overpayment to Deposit Account No. 50-1640.

Respectfully submitted,

By:



Roger L. Tate

Registration No. 27,399

RLT/sp

B

PATENT
ATTORNEY DOCKET: 031853.0003

11/Suppl B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application Of:)
Ralph W. BLUME et al.) Group Art Unit: 1615
Application Number: 09/559,542) Examiner: C. Evans
Filed: April 28, 2000)
For: GUAIFENESIN SUSTAINED RELEASE FORMULATION AND TABLETS)

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

Supplemental to the Amendment filed August 6, 2001 and in response to the Office Action mailed May 4, 2001, please further amend the above-captioned application as set forth below.

IN THE CLAIMS

Please amend claims 33, 42-44, 46 and 48 and add the following new claims 56-88, provided in a clean format in accordance with 37 C.F.R. § 1.121 as follows:

33. A modified release tablet having two portions, wherein a first portion comprises a first quantity of guaifenesin in an immediate release form which becomes fully bioavailable in the subject's stomach and a second portion comprises a second quantity of guaifenesin and a release-delaying matrix comprising a hydrophilic polymer and a water-insoluble polymer wherein the weight ratio of said hydrophilic polymer to said water-insoluble polymer is in the range of from about 1:1 to about 6.8:1, wherein said tablet demonstrates a C_{max} in a human subject equivalent to the C_{max} obtained when the first of three doses of a standard immediate release formulation having one third the amount of guaifenesin is dosed every four hours over a 12 hour period, and wherein said tablet also provides therapeutically effective bioavailability for at least twelve hours after a single dose in a human subject according to serum analysis.

34

B